Another US Stelara Settlement Arrives, This Time For Fresenius And Formycon

Deal With Johnson & Johnson Allows US Biosimilar Ustekinumab Entry In 2025

 
• By David Wallace
  
Red jigsaw pieces spelling out '2025'
The pieces are starting to fall into place for a series of ustekinumab biosimilar launches in the US in 2025 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business